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Abstract
Background: Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer,
must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes.
The objective of this study was to investigate the impact of CYP2D6 polymorphisms on (Z)-endoxifen-directed
tamoxifen metabolism and to assess the usefulness of CYP2D6 genotyping for identifying patients who are likely
to have insufficient (Z)-endoxifen concentrations to benefit from standard therapy.
Methods: Blood samples from 279 Polish women with breast cancer receiving tamoxifen 20 mg daily were
analyzed for CYP2D6 genotype and drug metabolite concentration. Steady-state plasma levels of tamoxifen
and its 14 metabolites were measured by using the ultra-performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) method.
Results: In nearly 60 % of patients, including over 30 % of patients with fully functional CYP2D6, (Z)-endoxifen
concentration was below the predefined threshold of therapeutic efficacy. The most frequently observed CYP2D6
genotype was EM/PM (34.8 %), among which 83.5 % of patients had a combination of wild-type and *4 alleles.
Plasma concentration of five metabolites was significantly correlated with CYP2D6 genotype. For the first time,
we identified an association between decreased (E/Z)-4-OH-N-desmethyl-tamoxifen-β-D-glucuronide levels (r2 = 0.23;
p < 10−16) and increased CYP2D6 functional impairment. The strongest correlation was observed for (Z)-endoxifen,
whose concentration was significantly lower in groups of patients carrying at least one CYP2D6 null allele, compared
with EM/EM patients. The CYP2D6 genotype accounted for plasma level variability of (Z)-endoxifen by 27 % (p < 10−16)
and for the variability of metabolic ratio indicating (Z)-endoxifen-directed metabolism of tamoxifen by 51 % (p < 10−43).
Conclusions: The majority of breast cancer patients in Poland may not achieve a therapeutic level of (Z)-endoxifen
upon receiving a standard dose of tamoxifen. This finding emphasizes the limited value of CYP2D6 genotyping in
routine clinical practice for identifying patients who might not benefit from the therapy. In its place, direct monitoring
of plasma steady-state (Z)-endoxifen concentration should be performed to personalize and optimize the treatment.
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Background
Tamoxifen is a selective estrogen receptor (ER) modula-
tor commonly used for the treatment or prevention of
hormone receptor-positive breast cancer, as well as for
chemoprevention in women at high risk of developing
breast cancer. Five years of tamoxifen treatment after
surgery reduces the annual recurrence rate of ER-positive
breast cancers by almost half and reduces the mortality
rate by a third [1]. However, significant interindividual
variability of tamoxifen efficacy is observed and disease re-
curs in 30–50 % of patients receiving adjuvant therapy [1].
Responsiveness to tamoxifen depends to a considerable
degree on genetic variability in the level of patients’ drug-
metabolizing enzymes.
Tamoxifen is a prodrug extensively metabolized via an
enzymatic network predominantly including cytochrome
P450 (CYP) isomers. At least 36 phase I tamoxifen me-
tabolites have been recently described [2, 3]. The drug is
primarily metabolized to N-desmethyl-tamoxifen (NDM-
Tam), the most abundant metabolite in patients’ plasma,
and 4-hydroxy-tamoxifen (4-OH-Tam), which are fur-
ther converted to the secondary metabolite 4-hydroxy-
N-desmethyl-tamoxifen (4-OH-NDM-Tam; endoxifen)
[4]. Both endoxifen and 4-OH-Tam exhibit 30- to 100-
fold higher anti-estrogenic potency than NDM-Tam or
tamoxifen itself, with respect to their affinity for ER and
suppression of estrogen-dependent breast cancer MCF7
cells proliferation, and are considered as the active tamoxi-
fen metabolites responsible for the overall therapeutic drug
activity [5–7]. Chemically, tamoxifen is a pure Z-isomer
and its metabolites are formed primarily in the Z-form [8].
Recently, (Z)-isomers of endoxifen and 4-OH-Tam were
found to exert the strongest ER inhibition among tamoxifen
metabolites, with half maximal inhibitory concentration
(IC50) values of 3 nmol/l and 7 nmol/l, respectively [2].
The major enzyme responsible for the conversion of
tamoxifen to endoxifen and 4-OH-Tam is CYP2D6 [9].
There is great interindividual variability in CYP2D6
enzyme activity due to, at least in part, genetic poly-
morphisms in the CYP2D6 gene. So far, over 140 al-
lelic variants of CYP2D6 have been described and a
substantial part of these are associated with reduced
or absent activity of the encoded enzyme [10]. With
regard to the combination of carried alleles (CYP2D6
genotype), each individual can be classified into one of
four phenotypic groups: ultra-rapid- (UM), extensive- (EM)
(wild type; wt), intermediate- (IM) or poor-metabolizer
(PM) [11]. Patients with IM or PM phenotypes, represented
by genetic variants associated with low or absent CYP2D6
activity, produced significantly less (Z)-endoxifen than wt
allele carriers [9, 12, 13], and an increase in the plasma con-
centration of this metabolite was observed in accordance
with the number of functional alleles [2]. Nonetheless, it is
believed that CYP2D6 genotypes explain no more than
40 % of the variability of steady-state concentration of
(Z)-endoxifen [2]. Some concomitant medications, such
as those used for the treatment of different mental disor-
ders, have been shown to significantly inhibit CYP2D6, re-
ducing overall production of active tamoxifen metabolites,
especially in patients of the EM phenotype [13].
Several reports suggest that (Z)-endoxifen is the most
potent tamoxifen metabolite in terms of its relative
contribution to the drug’s anticancer effectiveness. Its
anti-ER activity is comparable to that of (Z)-4-OH-Tam,
but its plasma steady-state concentration in patients
chronically treated with tamoxifen is several-fold higher
than 4-OH-Tam [6, 9, 14]. Moreover, at the concentrations
observed in CYP2D6 PM patients, the concentration-
dependent endoxifen effects on ER degradation [15],
global estrogen-induced gene expression in MCF7 cells
[16], or tumor growth inhibition in a MCF7 xenograft
bearing mouse model [17], were shown to have little or
no effect.
Recently, a long-term tamoxifen treatment outcome
study indicated that patients with (Z)-endoxifen plasma
level below a threshold of 5.97 ng/ml may not benefit
from the adjuvant therapy [12]. For patients with higher
metabolite concentrations, a 26 % lower breast cancer
recurrence rate was observed, defining for the first time
a therapeutically beneficial threshold level of endoxifen.
It is suggested that over 20 % of treated patients may
not achieve sufficiently high endoxifen exposure [12, 18].
However, in CYP2D6 PM or IM patients, a daily dose in-
crease from 20 mg to 30–40 mg of tamoxifen was found
to significantly raise endoxifen concentrations to levels
above or near the efficacy threshold [18–21]. As such,
tamoxifen treatment outcomes might be improved by
predicting which patients are likely to have low endoxifen
levels and by ensuring the appropriate hormonal therapy
regimen or dose accordingly.
The main objective of this study was to determine the
CYP2D6 allele and genotype frequencies and their associa-
tions with (Z)-endoxifen-directed tamoxifen metabolism
in Polish breast cancer patients treated with the standard
daily dose of 20 mg of tamoxifen. The steady-state plasma
level of tamoxifen and its 14 metabolites were measured
by a method of ultra-performance liquid chromatography
tandem mass spectrometry (UPLC-MS/MS) and the
metabolic ratio (MR) of (Z)-endoxifen concentration
to the sum of the remaining measured compounds was cor-
related with the patients’ CYP2D6 genotype. Unexpectedly,
nearly 60 % of patients had (Z)-endoxifen plasma level
below the 5.97 ng/ml efficacy threshold. In total, our find-
ings emphasized the limited value of CYP2D6 genotyping
for the prediction of achieving therapeutic levels of (Z)-
endoxifen in routine clinical practice. Rather, the direct
measurement of steady-state (Z)-endoxifen plasma level
should be performed to monitor the actual metabolite
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level for personalizing and optimizing the tamoxifen
treatment.
Methods
Ethic statement
All enrolled patients were Polish Caucasians recruited at
Maria Sklodowska-Curie Memorial Cancer Center-Institute
of Oncology in Warsaw between mid-2012 and mid-2014.
The local ethics committee approved the study and all
participants provided written informed consent. The
study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki.
Patients and blood sample collection
This study included 285 unselected women with verified
hormone receptor-positive breast cancer who had taken
tamoxifen at a standard 20 mg daily dose for at least one
month to ensure steady-state blood concentration of
drug and its metabolites. Selective serotonin reuptake in-
hibitors (SSRIs) intake was not a criterion for exclusion
because information about SSRI uptake is not obligatorily
recorded in routine clinical practice in Poland and
therefore adequate data from medical databases was not
available for objective monitoring. ER and progesterone
receptor (PR) status were evaluated by enzyme immuno-
assay or immunohistochemistry (IHC). Human epidermal
growth factor receptor 2 (HER2) expression was estimated
by IHC and fluorescence in situ hybridization (FISH)
methods. Nodal status was determined according to
the International Union Against Cancer tumor-node-
metastasis (TNM) classification.
Two peripheral blood samples taken from each patient
were put into Monovettes® tubes containing K-EDTA as
an anticoagulant (Sarstedt, Numbrecht, Germany), for
plasma isolation, and for genomic DNA extraction and
genotyping. Plasma was immediately separated by centri-
fugation and stored at −80 °C until UPLC-MS/MS ana-
lysis. Genomic DNA was extracted using QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany), following the
manufacturer’s protocol and quantified using a NanoDrop
1000 Spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA).
CYP2D6 genotyping
Isolated DNA samples were genotyped for CYP2D6 al-
leles in accordance with the nomenclature available at
http://www.cypalleles.ki.se/cyp2d6.htm [10]. To maximize
CYP2D6 phenotype prediction, the individual TaqMan
allelic discrimination assays were performed for 11 single-
nucleotide polymorphisms (SNPs) and two TaqMan Gene
Copy Number Assays for the gene deletion or duplication
(Applied Biosystems, Foster City, CA, USA), according to
manufacturer’s instructions. A SensiMix™ II Probe Kit
(Bioline Ltd, London, United Kingdom) and a 7900HT
Real-Time PCR system (Life Technologies, USA) were
used for the assays. The measured allele and relevant
SNP characteristics are presented in Additional file 1.
Each allele was assigned to one of four phenotypic cat-
egories according to its associated enzyme function. PM
(non-functional) alleles include: CYP2D6*3, *4, *5, *6, *7;
IM (reduced function) alleles include: CYP2D6*9, *10, *17,
*41; EM (wt; fully functional) alleles include CYP2D6*1
and *2; UM (increased function) alleles include: duplica-
tion of EM variants of the gene, such as CYP2D6*1XN
and *2XN. Patients were assigned a CYP2D6 genotype
depending on the combination of alleles they carry, as
PM/PM, IM/PM, IM/IM, EM/PM, EM/IM, EM/EM or
EM/UM.
Quantifying tamoxifen and its metabolites in plasma
Plasma concentration of tamoxifen and its 14 key
metabolites: NDM-Tam, (Z)-endoxifen, (E)-endoxifen,
3-OH-NDM-Tam, 4′-OH-NDM-Tam, (Z)-4-OH-Tam,
3-OH-Tam, 4′-OH-Tam, (Z)-α-OH-Tam, (E)-α-OH-Tam,
Tam-N-oxide, Tam-N-β-D-glucuronide (Tam-N-gluc), (E/
Z)-4-OH-NDM-Tam-β-D-glucuronide ((E/Z)-4-OH-NDM-
Tam-gluc), (E)-4-OH-Tam-O-β-D-glucuronide ((E)-4-OH-
Tam-O-gluc) were measured using the UPLC-MS/MS
method. All the above compounds, as well as deuterated
internal standards (ISs): Tam-d5, NDM-Tam-d5 and
(Z)-4-OH-Tam-d5, were purchased from Toronto Research
Chemicals (North York, ON, Canada). For sample prep-
aration and UPLC-MS/MS the following chemicals were
used: acetonitrile, methanol and formic acid (99 %) from J.
T. Baker (Avantor Center Valley, PA USA), ammonium
formate from Fluka (Buchs, Switzerland), and ultrapure
Milli-Q® water (Millipore Corp., Billerica, MA, USA).
Sample preparation was carried out as described by
Dahmane et al. [22], with slight modifications, including
protein precipitation by acetonitrile. Briefly, 100 μl of
plasma was mixed with 300 μl of ISs solution (3.3 ng/ml
of Tam-d5, 3.3 ng/ml of NDM-Tam-d5 and 4.2 ng/ml of
(Z)-4-OH-Tam-d5) in acetonitrile. After vortexing and
centrifugation (10 min; 18,000× g), 350 μl of clear super-
natant was evaporated under nitrogen in 55 °C. Finally,
samples were dissolved in 100 μl of 10 mM ammonium
formate in 50 % methanol.
For sample separation, an Acquity UPLC system equipped
with Acquity BEH Shield RP18 column (100 × 2.1 mm,
1.7 μm particle size) (Waters, Milford, MA, USA) was
used. The column was thermostatted at 70 °C. The mo-
bile phase A consisted of ultrapure water, and phase B
consisted of 0.1 % formic acid in acetonitrile. The flow
rate was 0.6 ml/min and the total run time was 16 min
per sample under nonlinear gradient condition as fol-
lows: 10 % to 80 % B for 12 min (concave curve), 80 %
B for 2 min, 95 % B for 1 min and 10 % B for 1 min.
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Detection was performed on a triple quadrupole mass
spectrometer Xevo TQ-MS (Waters) in the positive ion
electrospray ionization mode, with general mass spectrom-
etry (MS) parameters as follows: capillary voltage, 3 kV;
desolvation temperature, 550 °C; desolvation gas (nitro-
gen) flow, 1000 l/h; cone gas (nitrogen) flow, 100 l/h and
collision gas (argon) flow, 0.15 ml/min. Waters QuanLynx
software was used for chromatograms integration and
quantitation. The Additional file 2 details a description
of the calibration method, the metabolite standards linear-
ity range and the chosen MS/MS transition parameters.
Statistical analyses
Mean concentration of tamoxifen and its metabolites was
calculated for the seven functional CYP2D6 genotype pre-
dicted categories: EM/UM, EM/EM, EM/IM, EM/PM,
IM/IM, IM/PM and PM/PM. The Hardy-Weinberg equi-
librium was checked using Chi-square test. Chi-square test
was also used to qualitatively check the correlation of (Z)-
endoxifen plasma level with the MR of (Z)-endoxifen to
the sum of the remaining metabolites. The relevant cat-
egories were as follow: for (Z)-endoxifen - below/above
6 ng/ml; for MR - below/above 0.0146. The cutoff value of
0.0146 for the MR was estimated with simple linear re-
gression fit for (Z)-endoxifen level and MR relationship.
Linear model (ordinary least squares) was fitted inde-
pendently for ten metabolite concentrations and two
MRs in six functional groups (indicator variables) with
EM/EM as a reference to examine whether there was a
linear association between the measured metabolite con-
centration and CYP2D6 genotype. Student’s t statistics
was used to test if fitted coefficients were significantly
different than 0. The Bonferroni correction was used to
adjust p-value significance threshold for multiple compari-
sons and p < 6.9 × 10−4 (0.05/12 metabolites/6 genotypes)
was considered significant. Calculations were performed
using R statistical software package (http://www.r-project.
org/) [23]. The p-value for Spearman rank correlation co-
efficient r was calculated by using the AS 89 algorithm
and was used as a marker of significance of the association
between metabolite plasma concentration and CYP2D6
genotype. Squared r was used to indicate the proportion
of variation of one variable which could be explained by
the other variable.
Results
Patients
The plasma samples were obtained from 285 women with
hormone receptor-positive breast cancer (median age at
diagnosis 55, range 25-95) receiving standard treatment of
20 mg of tamoxifen daily. The median time period between
the start of the tamoxifen treatment and taking a blood
sample for analysis was 21.5 months (range 1–70). Among
the enrolled patients, six had plasma drug concentrations
of less than 10 % of the mean tamoxifen levels across all
patients, and were excluded from the association analyses
between CYP2D6 genotype and tamoxifen metabolism.
The clinical characteristics for the remaining 279 patients
are listed in Table 1.
CYP2D6 genotype frequency
The frequencies of measured CYP2D6 alleles are indi-
cated in Additional file 1. There was no deviation from
the Hardy-Weinberg equilibrium for any genetic variant.
Altogether, wt function alleles (*1, *2) were present in
60 % of enrolled patients. Among the alleles harboring
impaired activity of the encoded enzyme, four with null
activity (*4, *5, *6, *7) and four with reduced activity (*9,
*10, *17, *41), the most frequently observed were alleles
*4 (22.3 %) and *41 (7.7 %).
The appropriate CYP2D6 genotype was assigned to 279
patients, who were further categorized into seven groups
with respect to the encoded enzyme activity: EM/UM
(6.5 %), EM/EM (31.2 %), EM/IM (15.4 %), EM/PM
(34.8 %), IM/IM (1.1 %), IM/PM (3.9 %) and PM/PM
(7.2 %) (Table 2). Among the most frequently occurring
EM/PM genotype, 81 out of 97 patients (83.5 %) had a
combination of alleles wt and *4.
Tamoxifen and its metabolites plasma concentration
The plasma steady-state concentrations of tamoxifen and
14 of its metabolites were measured using UPLC-MS/MS.
In the case of the two pairs of isobaric compounds,
(Z)-endoxifen and 3-OH-NDM-Tam, and (Z)-4-OH-
Tam and 3-OH-Tam, each of the respective metabolites
were quantified as a sum because of inability to obtain
distinct chromatographic separation between the two
compounds. However, based on previous reports [2, 22,
24], the plasma concentrations of both 3-OH-Tam and
3-OH-NDM-Tam are several-fold lower than their 4-
isomer counterparts and for simplicity, the respective
measures were further referred to as purely (Z)-endoxifen
and (Z)-4-OH-Tam concentrations. Remaining metabo-
lites, including selected glucuronides, Tam-N-Oxide,
4′-OH-Tam and 4′-OH-NDM-Tam derivatives, as well
as selected (E)- and (Z)-isomers, have been quantified
separately (see Additional file 2 for the examples of
sample calibration chromatograms).
For some compounds, we obtained a good signal-to-
noise (S/N) ratio and clearly defined chromatography
peaks at very low concentration. However, we were unable
to obtain satisfactory linear calibration curves starting
from such low levels. Thus, we decided to report the mea-
sures below the level of linearity range (LOLR), in cases
where acceptable S/N ratio (>10) and the peak parameters
were obtained, but these measures should be considered
only as “estimated concentrations”. The linearity ranges of
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the calibration curve for standard metabolites are listed in
Additional file 2.
The mean and median plasma concentrations with the
range for each metabolite in 279 patients are included in
Table 3. For tamoxifen and for most of its metabolites, a
very wide variability of concentrations was observed be-
tween individuals. NDM-Tam and tamoxifen were the
most abundant, with a range of 33.2–810.2 ng/ml (mean
235.5 ± 97.0) and 41.4–402.1 ng/ml (173.5 ± 67.7), respect-
ively. Next, high levels of Tam-N-oxide (13.5 ± 7.4 ng/ml)
were observed. As expected, of the two known clinically
active metabolites, the mean concentration level of (Z)-
endoxifen was higher than that of (Z)-4-OH-Tam (5.6 ± 3.3
vs. 2.5 ± 1.2 ng/ml). In agreement with other studies [2, 24],
(E)-endoxifen was present only in trace amounts (below
the LOLR) in the plasma of 30 patients (10.8 %). Similarly,
the plasma concentration of (Z)-α-OH-Tam was within the
calibration linearity range in only four samples, and was
not detected at all in 116 patients (41.6 %). Trace amounts
of (E)-α-OH-Tam were measured in the plasma of 271
patients, but in 239 of these (85.7 %) the estimated con-
centration was below the LOLR.
Association of CYP2D6 genotype and tamoxifen
metabolites concentration
Additional file 1 includes the list of measured plasma
concentrations of analyzed compounds and assigned
CYP2D6 genotypes of all patients studied. The linear
modeling indicated that the concentrations of five tamoxi-
fen metabolites were significantly (p < 6.9 × 10−4) correlated
with CYP2D6 genotype (Fig. 1a, c, e-g). The level of
NDM-Tam and 4′-OH-NDM-Tam tended to decrease
in accordance with the number of functional enzyme
alleles, showing significantly higher values for EM/PM
and PM/PM genotypes, compared with EM/EM. Con-
versely, significantly lower concentrations of (E/Z)-4-OH-
NDM-Tam-gluc were observed among EM/PM and
PM/PM patients than in EM/EM patients.
The most evident association with CYP2D6 genotype
was observed for plasma (Z)-endoxifen concentration
(Fig. 1a), the mean level of which was significantly de-
creased in PM/PM (1.8 ng/ml), IM/PM (2.3 ng/ml) and
EM/PM (4.9 ng/ml) genotype carriers, as compared with
EM/EM (7.3 ng/ml) carriers. The concentration of (Z)-
4-OH-Tam, the other active metabolite, was significantly
Table 1 Characteristics of patients
Total N = 279
Number of patients (%)
Age at diagnosis, median (range years) 55 (25 – 95)
Duration of tamoxifen treatment, median
(range months)
21.5 (1 – 70)
Tamoxifen therapy
neoadjuvant 7 (2.5)
adjuvant 258 (92.5)
metastasis 14 (5)
Breast cancer treatment
surgery 276 (98.9)
received radiation 148 (53)
received chemotherapy 232 (83.2)
Hormonal status at diagnosis
premenopausal 81 (29)
postmenopausal 115 (41.2)
unknown 83 (29.7)
Tumor size
T1 105 (37.6)
T2 142 (50.9)
T3 20 (7.2)
T4 10 (3.6)
unknown 2 (0.7)
Node status
N 0 132 (47.3)
N 1 112 (40.3)
N 2 - 3 30 (10.8)
unknown 5 (1.8)
Differential grade
G1 39 (14)
G2 129 (46.2)
G3 67 (24)
unknown 44 (15.8)
Histology
ductal 205 (73.5)
lobular 30 (10.8)
other 38 (13.6)
unknown 6 (2.2)
Hormone receptor status
Estrogen+ 269 (96.4)
Progesterone+ 238 (85.3)
Both 230 (82.4)
Table 1 Characteristics of patients (Continued)
HER2 status
positive 64 (22.9)
negative 210 (75.3)
unknown 5 (1.8)
Tumor characteristics were at diagnosis. HER2: human epidermal growth factor
receptor 2
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lower only in PM/PM patients (1.5 ng/ml vs. 2.7 ng/ml
in EM/EM). The MR of (Z)-endoxifen plasma concen-
tration to the sum of concentrations of the remaining
measured compounds, which illustrates the direction of
tamoxifen metabolism to (Z)-endoxifen production, showed
a strong association with the CYP2D6 genotype predicted
functional group, increasing in accordance with the number
of active alleles (Fig. 1b). For the MR of the levels of
(Z)-4-OH-Tam and the sum of the remaining compounds,
a much less pronounced association was indicated, al-
though stronger than for steady-state (Z)-4-OH-Tam
concentration (Fig. 1c, d).
The Spearman correlation coefficient indicated that
27 % (p < 10−19) of the variability in plasma levels of (Z)-
endoxifen, and 51 % (p < 10−43) of the variability in its
MR, was accounted for by the CYP2D6 genotype. For
(Z)-4-OH-Tam, the CYP2D6 genotype accounted for only
5 % (p < 10−3) and 15 % (p < 10−10) variability in plasma
level and corresponding MR, respectively. Additionally,
23 % (p < 10−16) of (E/Z)-4-OH-NDM-Tam-gluc, 18 %
(p < 10−12) of 4′-OH-NDM-Tam and 13 % (p < 10−9) of
NDM-Tam plasma level variability was associated with
the CYP2D6 genotype.
Low (Z)-endoxifen concentration and the profile of
tamoxifen metabolism
Based on UPLC-MS/MS analyzed plasma concentra-
tions, the (Z)-endoxifen level was below the predefined
threshold value of 5.97 ng/ml in 167 patients (59.9 %).
There was a clear correlation (Chi-square, p = 3.8 × 10−10)
between the number of patients with low active metabolite
concentration and predicted CYP2D6 deficient functional
category (Fig. 2). Among PM/PM, IM/PM and IM/IM
genotype carriers, the measured (Z)-endoxifen plasma
concentration was below the threshold level in all patients.
Next, 61 % and 72 % of patients from EM/PM and EM/
IM groups, and 33 % and 36 % of patients from EM/EM
and EM/UM groups, respectively, exhibited (Z)-endoxifen
levels below the threshold.
Correlation analysis between (Z)-endoxifen concentration
and the corresponding MR revealed that the tamoxifen
metabolism directed to the production of (Z)-endoxifen
accounted for 61 % (r = 0.78, p = 10−15) variability of the
absolute plasma level of (Z)-endoxifen. The MR value of
0.0146 was delineated as the threshold corresponding to
the (Z)-endoxifen 6 ng/ml threshold level (Fig. 3). For 226
patients (81 %), the steady-state level of (Z)-endoxifen and
MR values was consistent: for 84 women both values were
above, and for 142 both values were below, the respective
thresholds (6 ng/ml and 0.0146). In 25 patients (9 %) the
level of (Z)-endoxifen was low (<6 ng/ml) despite the
proper profile of tamoxifen metabolism (MR > 0.0146),
and conversely, in 28 patients (10 %) the metabolite plasma
level was > 6 ng/ml, although, the MR was below the
threshold.
Altogether, our results of association analyses between
CYP2D6 genotype and (Z)-endoxifen concentration in
the plasma, underlined the primary role of CYP2D6 in
the profile of tamoxifen metabolism, specifically with re-
spect to the production of NDM-Tam and (Z)-endoxifen.
However, a significant proportion of active metabolite
concentration depends on other genetic or environmental
factors that alter the activity of the CYP2D6 enzyme or
tamoxifen metabolism profile.
Discussion
It is widely accepted that (Z)-endoxifen is the main active
tamoxifen metabolite responsible for the overall clinical
efficacy of the prodrug tamoxifen [12, 13, 19, 25, 26].
Table 2 The CYP2D6 genotype frequency
Genotype N = 279 Frequency (%)
EM/EM *1/*2 44 15.8
n = 87 (31.2 %) *1/*1 33 11.8
*2/*2 10 3.6
EM/IM *1/*41 24 8.6
n = 43 (15.4 %) *2/*41 10 3.6
*1/*10 7 2.5
*2/*10 2 0.7
EM/PM *1/*4 51 18.3
n = 97 (34.8 %) *2/*4 30 10.8
*1/*5 6 2.2
*1/*3 4 1.4
*2/*5 3 1.1
*1/*6 1 0.4
*2/*3 1 0.4
*2/*6 1 0.4
IM/IM *41/*41 1 0.4
n = 3 (1.1 %) *10/*10 1 0.4
*10/*41 1 0.4
IM/PM *4/*41 6 2.2
n = 11 (3.9 %) *4/*10 3 1.1
*4/*17 1 0.4
*5/*41 1 0.4
PM/PM *4/*4 15 5.4
n = 20 (7.2 %) *3/*4 2 0.7
*4/*5 2 0.7
*4/*6 1 0.4
UM *1/*2 (xN) 10 3.6
n = 18 (6.5 %) *1/*1 (xN) 5 1.8
*2/*2 (xN) 3 1.1
EM extensive-metabolizer, IM intermediate-metabolizer, PM poor-metabolizer,
UM ultra-rapid-metabolizer
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The plasma steady-state concentration of (Z)-endoxifen
in drug-treated breast cancer patients is strongly asso-
ciated with the number of functional CYP2D6 alleles
[2]. Recently, it has been suggested that the efficacy of
tamoxifen therapy depends on meeting a threshold plasma
level of (Z)-endoxifen rather than a linear dose-response
effect [12]. Accordingly, the identification of patients
who are unlikely to attain clinically sufficient plasma
(Z)-endoxifen levels is of great interest for individual
drug dose adjustment and therapy optimization.
To verify the usefulness of CYP2D6 genotyping for the
prediction of tamoxifen metabolism impairment, i.e., not
achieving therapeutically beneficial (Z)-endoxifen exposure,
we measured the steady-state concentration of tamoxifen
and its metabolites in the plasma of nearly 280 Polish
patients with breast cancer that were routinely treated
with the standard 20 mg daily dose of the drug. Based
on the patients’ CYP2D6 alleles, all were classified into
one of seven functional groups of the enzyme.
The CYP2D6 allele and genotype frequencies among
the studied patients were as expected for the Caucasian
population, and similar to those obtained by others [2,
11, 19, 20, 27–29], with the most frequently occurring
allele *4 (22.3 %), encoding the CYP2D6 enzyme of null
activity (Additional file 1), and wt/*4 genotype (29.1 %)
among the impaired activity enzyme carriers (Table 2).
Compared with previous studies [2, 19, 27, 30], a slightly
higher frequency of predicted EM/PM phenotype was
observed among Polish patients (34.8 % vs. mean 23.8 %),
but an average frequency of other functional groups, in-
cluding PM/PM (7.2 % vs. 6.6 %), was consistent.
We adopted a sensitive UPLC-MS/MS method for the
direct measurement of the drug and its metabolites in
plasma [2, 22]. Originally, the method was developed for
the quantitation of tamoxifen and seven of its metabolites,
and, for the first time, 4′-OH derivatives were identified in
the plasma of breast cancer patients [22]. In our study, we
were successful in obtaining a perfect chromatographic
separation of the drug and 12 of its metabolites, including
both 4′-OH and α-OH derivatives, as well as Tam-N-
oxide as an alternatives to the (Z)-endoxifen-directed
pathway of tamoxifen metabolism. Moreover, three glu-
curonide conjugates were measured as phase II metabolite
representatives. Consistent with previous reports, a wide
range of concentrations of tamoxifen and of most of its
primary metabolites were indicated (Table 3) [2, 12, 28].
According to linear modeling analysis, the plasma con-
centrations of five metabolites were significantly (p <
6.9 × 10−4) correlated with the CYP2D6 genotype (Fig. 1).
For the first time, we have indicated an association be-
tween lower (E/Z)-4-OH-NDM-Tam-gluc levels (r2 = 0.23;
p < 10−16) and an increasing degree of CYP2D6 functional
impairment. In turn, consistent with other reports [12, 31],
both NDM-Tam and 4′-OH-NDM-Tam were inversely
correlated with the number of CYP2D6 deficient alleles.
Furthermore, both active metabolites tended to decrease
in proportion to the degree of CYP2D6 deficiency, with
the strongest correlation being observed for (Z)-endoxifen,
whose concentration was significantly lower in groups
of patients carrying at least one CYP2D6 null allele,
compared with EM/EM. In total, the CYP2D6 genotype
accounted for plasma level variability of (Z)-endoxifen
and 4-OH-Tam by 27 % (p < 10−16) and 5 % (p < 10−3),
respectively. However, the CYP2D6 genotype accounted
for 51 % (p < 10−43) of the variability of the MR for (Z)-
endoxifen-directed drug metabolism. CYP2D6 deficiency
has previously been shown to be associated with lower
levels of both tamoxifen active metabolites [2, 12, 20, 27]
Table 3 The steady-state plasma concentration of tamoxifen and its metabolites
[ng/ml] Mean SD Median Min Max Not detecteda
N = 279 (%)
Tamoxifen 173.53 67.68 169.76 41.4 402.10 0 (0)
NDM-Tam 235.53 97.04 220.53 33.20 810.16 0 (0)
(Z)-Endoxifen + 3-OH-NDM-Tam 5.55 3.26 4.90 0.55 18.23 0 (0)
(Z)-4-OH-Tam + 3-OH-Tam 2.46 1.20 2.45 0.12 5.66 0 (0)
(E)-Endoxifen 0.02 0.07 0 0.03 0.37 249 (89.2)
4′-OH-Tam 3.13 1.32 2.93 0.37 8.72 0 (0)
4′-OH-NDM-Tam 3.84 1.93 3.56 0.19 15.66 1 (0.4)
Tam-N-oxide 13.47 7.43 11.62 1.41 58.03 0 (0)
(E)-4-OH-Tam-O-gluc 0.23 0.17 0.18 0.03 1.19 1 (0.4)
(E/Z)-4-OH-NDM-Tam-gluc 1.12 1.02 0.88 0.10 11.49 0 (0)
(E/Z)-Tam-N-gluc 0.32 0.32 0.24 0.03 2.45 1 (0.4)
(E)-α-OH-Tam 0.36 0.17 0.37 0.02 1.02 8 (2.9)
(Z)-α-OH-Tam 0.04 0.03 0.04 0.02 0.19 116 (41.6)
aThe number and (%) of patients with no detectable plasma concentration of compounds
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and the correlation of plasma level variability with CYP2D6
genotype was estimated to be 39 % for (Z)-endoxifen and
9 % for 4-OH-Tam [2]. Altogether, our results strongly
confirmed the importance of CYP2D6 function in (Z)-
endoxifen-directed metabolism of tamoxifen, as illustrated
in Fig. 4 where the metabolic pathway responsible for the
production of NDM-Tam and (Z)-endoxifen is highlighted
by the strength of association of metabolite concentration
with CYP2D6 genotype.
From 36 known phase I metabolites of tamoxifen [3],
only 3–4 are commonly estimated, including 4-OH-Tam
and (Z)-endoxifen [12, 14, 27, 28, 32, 33]. Some recent
studies have shown the importance of highly selective
chromatographic separation for the accurate quantitation
of measured compounds [22, 24, 34]. Several metabolites
have molecular masses and fragmentation patterns similar
to endoxifen and 4-OH-Tam, making them indistinguish-
able by MS. The lack of their proper liquid chromatog-
raphy (LC) separation resulted in a factor of 2–3 times
overestimation of active metabolite levels [24]. Although
we managed to separate α-OH and 4′-OH derivatives of
(Z)-endoxifen and 4-OH-Tam, we were unable to separate
their 3-isomer counterparts. Nonetheless, the average
concentration of (Z)-endoxifen in the plasma of Polish
patients (5.6 ng/ml) was lower than in most other studies,
where it ranged from 6.21 ng/ml to as high as 84.1 ng/ml
[2, 13, 18, 28, 32, 33, 35, 36], some of which could possibly
be falsely elevated because of peak coelution. The steady-
state (Z)-endoxifen concentration might be related to
the length of tamoxifen treatment. However, the median
duration of tamoxifen therapy in our study was over
20 months, which seems to be more than long enough,
considering the half-life of the drug in human plasma is
5–7 days [37].
The most unexpected result of our study was that in
nearly 60 % of patients, the plasma concentration of (Z)-
endoxifen was below the predefined 5.97 ng/ml level of
clinical efficacy, including in over 30 % of patients with
fully active CYP2D6 (EM/EM). Recently, it was suggested
that slightly more than 20 % of women receiving a 20 mg
dose of tamoxifen might not achieve high enough (Z)-
endoxifen exposure [12, 18]. These divergent results may
be due to the concomitant use of drugs that can affect
CYP2D6 activity, especially among EM/EM patients.
For example, some SSRIs, which are used in up to 30 %
of breast cancer patients for depression or the relief of
tamoxifen-induced menopausal symptoms such as hot
flashes, were found to be strong CYP2D6 inhibitors [9,
13, 14]. Specifically, coadministration of paroxetine, an
SSRI, was associated with a significant decrease in plasma
endoxifen concentration, primarily in patients with the
EM phenotype (by 58–72 %) [9, 13, 14]. It is now recom-
mended that the use of strong CYP2D6 inhibitors be
avoided where other treatment is possible.
The other critical factor for the overall steady-state
(Z)-endoxifen level is the degree of compliance with
tamoxifen therapy [26]. It has been estimated that only
half of the patients remain on therapy after the 4th
year [38]. Not adhering to the treatment was more
commonly observed among patients with fully active
CYP2D6 than those with null activity [39], most likely
because they experience hot flashes more frequently
[40]. This might help explain the observed low (Z)-
endoxifen levels, despite having a MR over the threshold
(Fig. 3), in some of EM/EM patients in our study.
Concomitant medications and compliance with the
therapy were not reported in this study, which could be
considered as a limitation. Our goal, however, was to
Fig. 2 The steady-state concentration of plasma (Z)-endoxifen. The
mean concentration of the metabolite in each CYP2D6 genotype
group and the predefine threshold level of 6 ng/ml are indicated
(See figure on previous page.)
Fig. 1 Significant association of the CYP2D6 genotype with plasma concentration and molecular ratio of tamoxifen metabolites. a (Z)-endoxifen,
b The MR of (Z)-endoxifen/sum of the remaining measured compounds, c (Z)-4-OH-tamoxifen, d MR of (Z)-4-OH-tamoxifen/sum of the remaining
compounds, e N-desmethyl-tamoxifen, f 4′-OH-N-desmethyl-tamoxifen, g (E/Z)-4-OH-N-desmethyl-tamoxifen-β-D-glucuronide. The number of
patients (N) was as follow: EM/UM (18), EM/EM (87), EM/IM (43), EM/PM (97), IM/IM (3), IM/PM (11), PM/PM (20). The horizontal line indicates the
median plasma concentration, the box covers 25th-75th percentiles and the maximum length of each whisker is 1.5× the interquartile range; dots
outside the whiskers are outliers. Linear model (ordinary least squares) was fitted independently in six functional groups with EM/EM as a reference to
examine whether there was an association between the measured metabolite concentration and CYP2D6 phenotype. Student’s t statistics was used to
test if fitted coefficients were different than 0. The Bonferroni corrected p-value of less than 6.9 × 10−4 was considered significant. Significant associations
are marked with asterisk (*)
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estimate the predictive value of CYP2D6 genotyping for
achieving beneficial (Z)-endoxifen levels in routine clinical
practice, where incomplete knowledge, or sparse data, on
co-medication and self-reported adherence are frequent
obstacles in the clinical setting.
Apart from CYP2D6, other drug-metabolizing enzymes
may also contribute to the overall level of (Z)-endoxifen.
For example, polymorphic CYP2C9 was found to contribute
to 4-OH-Tam production, which is the source for 20–
30 % of total (Z)-endoxifen [2]. Also, the importance
of CYP3A5 [14] and CYP2C19 [41] allelic variation has
been suggested. In addition to the phase I metabolic
enzymes, the pharmacokinetics of tamoxifen may also be
influenced by phase II enzymes such as sulfotransferases
(SULTs) or uridine 5′-diphospho-glucuronyltransferases
(UGTs), which further metabolize active metabolites into
Fig. 3 The comparison between plasma steady-state concentration of (Z)-endoxifen level and corresponding metabolic ratio. The metabolic ratio
(MR) was estimated as (Z)-endoxifen plasma concentration divided by the sum of concentrations of the remaining measured compounds. The
MR value of 0.0146 was delineated as the correlation coefficient with the level of 6 ng/ml. The assigned CYP2D6 functional category, based on
CYP2D6 genotype, is indicated in color
Fig. 4 The (Z)-endoxifen-directed metabolism of tamoxifen according to the association of its metabolites concentration with CYP2D6 genotype.
The intensity of gray shading corresponds with the number of CYP2D6 genotype predicted functional groups with a significant (p < 6.9 × 10−4)
association with metabolite plasma concentration. White indicates no association and black indicates association with three genotypes, as indicated by
linear modeling (see Fig. 1)
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hydrophilic derivatives that can be excreted. Genetic poly-
morphism of SULT1A2 seems to play a role in maintaining
optimal levels of both active tamoxifen metabolites, which
are its substrates. The carriers of null SULT1A2 enzyme
alleles had significantly higher plasma concentrations of
endoxifen and 4-OH-Tam [28], and specific combinations
of CYP2D6 and SULT1A2 allelic variants seem to sig-
nificantly affect an overall response to tamoxifen therapy
[42]. Polymorphic variants of different UGTs were also de-
scribed and were indicated to have the potential to alter
elimination rates of endoxifen and 4-OH-Tam by prolonging
or reducing their circulating half-lives [43]. The modifying
impact of genetic polymorphism in other tamoxifen-
metabolizing enzymes may account for the higher-than-
expected (Z)-endoxifen level, based on MR value.
In summary, we have confirmed the importance of
CYP2D6 activity in generating the overall (Z)-endoxifen
plasma level, although additional factors also contribute.
The mean steady-state plasma level of this active metabol-
ite in breast cancer patients treated with tamoxifen was
lower in our study than previously reported. In the major-
ity of patients, the (Z)-endoxifen concentration was below
the predefined level of therapeutic efficacy, suggesting that
a significant number of patients in Poland may not benefit
from the standard tamoxifen therapy.
Conclusions
In making clinical decisions, it is important to identify
patients who are likely to have insufficient (Z)-endoxifen
concentration to benefit from the standard tamoxifen
therapy. Admittedly, the CYP2D6 genetic polymorphism
has a major impact on (Z)-endoxifen level variation, but
it might be significantly modified by several other unpre-
dictable factors, such as concomitant use of CYP2D6
inhibitors or weak compliance. The lack of at least one
fully functional CYP2D6 allele may have a predictive
value for not achieving a clinically effective level of (Z)-
endoxifen among Polish patients, allowing us to consider
increasing the drug-dosing regimen before the treatment
starts. However, the true number of patients with low (Z)-
endoxifen is much higher than predicted and includes some
patients with fully active CYP2D6. In addition, increasing
the dose of the drug does not necessarily mean the metab-
olite level will be increased, and this needs to be verified.
Thus, the only reliable strategy to identify those individuals
who may need dose adjustment or optimization of the
treatment is the direct monitoring of (Z)-endoxifen
concentration.
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